Literature DB >> 28540658

Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.

Jacqueline London1, Claude Rouch2, Linh Chi Bui2, Elodie Assayag2, Benoit Souchet2, Fabrice Daubigney2, Hind Medjaoui2, Serge Luquet2, Christophe Magnan2, Jean Maurice Delabar2,3, Julien Dairou2,4, Nathalie Janel2.   

Abstract

Trisomy 21 (T21) or Down syndrome (DS) is the most common genetic disorder associated with intellectual disability and affects around 5 million persons worldwide. Neuroanatomical phenotypes associated with T21 include slight reduction of brain size and weight, abnormalities in several brain areas including spines dysgenesis, dendritic morphogenesis, and early neuroanatomical characteristics of Alzheimer's disease. Monoamine neurotransmitters are involved in dendrites development, functioning of synapses, memory consolidation, and their levels measured in the cerebrospinal fluid, blood, or brain areas that are modified in individuals with T21. DYRK1A is one of the recognized key genes that could explain some of the deficits present in individuals with T21. We investigated by high-performance liquid chromatography with electrochemical detection the contents and processing of monoamines neurotransmitters in four brain areas of female and male transgenic mice for the Dyrk1a gene (mBactgDyrk1a). DYRK1A overexpression induced dramatic deficits in the serotonin contents of the four brain areas tested and major deficits in dopamine and adrenaline contents especially in the hypothalamus. These results suggest that DYRK1A overexpression might be associated with the modification of monoamines content found in individuals with T21 and reinforce the interest to target the level of DYRK1A expression as a therapeutic approach for persons with T21.

Entities:  

Keywords:  Brain tissues; DYRK1A; High-performance liquid chromatography with electrochemical detection (HPLC-ED); Monoamine neurotransmitters; Trisomy 21 (T21); mBACtgDyrk1a mice

Mesh:

Substances:

Year:  2017        PMID: 28540658     DOI: 10.1007/s12035-017-0591-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  81 in total

1.  Monoamine metabolism in Down syndrome.

Authors:  D M Mann; J Lincoln; P O Yates; C M Brennan
Journal:  Lancet       Date:  1980 Dec 20-27       Impact factor: 79.321

2.  Blood-serotonin deficiency in Down's syndrome.

Authors:  J B Tu; H Zellweger
Journal:  Lancet       Date:  1965-10-09       Impact factor: 79.321

3.  Ts1Cje Down syndrome model mice exhibit environmental stimuli-triggered locomotor hyperactivity and sociability concurrent with increased flux through central dopamine and serotonin metabolism.

Authors:  Atsushi Shimohata; Keiichi Ishihara; Satoko Hattori; Hiroyuki Miyamoto; Hiromasa Morishita; Guy Ornthanalai; Matthieu Raveau; Abdul Shukkur Ebrahim; Kenji Amano; Kazuyuki Yamada; Haruhiko Sago; Satoshi Akiba; Nobuko Mataga; Niall P Murphy; Tsuyoshi Miyakawa; Kazuhiro Yamakawa
Journal:  Exp Neurol       Date:  2017-03-20       Impact factor: 5.330

4.  DYRK1A: a master regulatory protein controlling brain growth.

Authors:  Fayçal Guedj; Patricia Lopes Pereira; Sonia Najas; Maria-Jose Barallobre; Caroline Chabert; Benoit Souchet; Catherine Sebrie; Catherine Verney; Yann Herault; Mariona Arbones; Jean M Delabar
Journal:  Neurobiol Dis       Date:  2012-01-26       Impact factor: 5.996

5.  Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Rafael de la Torre; Susana de Sola; Gimena Hernandez; Magí Farré; Jesus Pujol; Joan Rodriguez; Josep María Espadaler; Klaus Langohr; Aida Cuenca-Royo; Alessandro Principe; Laura Xicota; Nathalie Janel; Silvina Catuara-Solarz; Gonzalo Sanchez-Benavides; Henri Bléhaut; Iván Dueñas-Espín; Laura Del Hoyo; Bessy Benejam; Laura Blanco-Hinojo; Sebastiá Videla; Montserrat Fitó; Jean Maurice Delabar; Mara Dierssen
Journal:  Lancet Neurol       Date:  2016-07       Impact factor: 44.182

6.  Down syndrome and Alzheimer's disease: Common pathways, common goals.

Authors:  Dean Hartley; Thomas Blumenthal; Maria Carrillo; Gilbert DiPaolo; Lucille Esralew; Katheleen Gardiner; Ann-Charlotte Granholm; Khalid Iqbal; Michael Krams; Cynthia Lemere; Ira Lott; William Mobley; Seth Ness; Ralph Nixon; Huntington Potter; Roger Reeves; Marwan Sabbagh; Wayne Silverman; Benjamin Tycko; Michelle Whitten; Thomas Wisniewski
Journal:  Alzheimers Dement       Date:  2014-12-12       Impact factor: 21.566

7.  Postnatal growth defects in mice with constitutive depletion of central serotonin.

Authors:  Nicolas Narboux-Nême; Gaelle Angenard; Valentina Mosienko; Friederike Klempin; Pothitos M Pitychoutis; Evan Deneris; Michael Bader; Bruno Giros; Natalia Alenina; Patricia Gaspar
Journal:  ACS Chem Neurosci       Date:  2012-12-15       Impact factor: 4.418

8.  Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer's Disease.

Authors:  Yannick Vermeiren; Jana Janssens; Tony Aerts; Jean-Jacques Martin; Anne Sieben; Debby Van Dam; Peter P De Deyn
Journal:  J Alzheimers Dis       Date:  2016-06-15       Impact factor: 4.472

Review 9.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

Review 10.  Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics.

Authors:  Nicole Créau
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

View more
  8 in total

1.  Alterations in the Serotonin and Dopamine Pathways by Cystathionine Beta Synthase Overexpression in Murine Brain.

Authors:  J London; F K Ndiaye; L C Bui; B Souchet; F Daubigney; C Magnan; S Luquet; J Dairou; N Janel; C Rouch
Journal:  Mol Neurobiol       Date:  2018-09-20       Impact factor: 5.590

2.  Altered development of dopaminergic neurons differentiated from stem cells from human exfoliated deciduous teeth of a patient with Down syndrome.

Authors:  Thanh Thi Mai Pham; Hiroki Kato; Haruyoshi Yamaza; Keiji Masuda; Yuta Hirofuji; Hiroshi Sato; Huong Thi Nguyen Nguyen; Xu Han; Yu Zhang; Tomoaki Taguchi; Kazuaki Nonaka
Journal:  BMC Neurol       Date:  2018-08-31       Impact factor: 2.474

3.  Down syndrome phenotype in a boy with a mosaic microduplication of chromosome 21q22.

Authors:  Franziska Schnabel; Mateja Smogavec; Rudolf Funke; Silke Pauli; Peter Burfeind; Iris Bartels
Journal:  Mol Cytogenet       Date:  2018-12-29       Impact factor: 2.009

4.  Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.

Authors:  Xiaojiang Tian; Lin Chen; Di Gai; Sijie He; Xuan Jiang; Ni Zhang
Journal:  Front Pharmacol       Date:  2022-03-25       Impact factor: 5.810

5.  DYRK1A Overexpression in Mice Downregulates the Gonadotropic Axis and Disturbs Early Stages of Spermatogenesis.

Authors:  Rodolphe Dard; Manon Moreau; Estelle Parizot; Farah Ghieh; Leslie Brehier; Nadim Kassis; Valérie Serazin; Antonin Lamaziere; Chrystèle Racine; Nathalie di Clemente; François Vialard; Nathalie Janel
Journal:  Genes (Basel)       Date:  2021-11-16       Impact factor: 4.096

6.  Down Syndrome in Brazil: Occurrence and Associated Factors.

Authors:  Mariana Rabello Laignier; Luís Carlos Lopes-Júnior; Raquel Esperidon Santana; Franciéle Marabotti Costa Leite; Carolina Laura Brancato
Journal:  Int J Environ Res Public Health       Date:  2021-11-14       Impact factor: 3.390

7.  microRNAs and Gene-Environment Interactions in Autism: Effects of Prenatal Maternal Stress and the SERT Gene on Maternal microRNA Expression.

Authors:  David Q Beversdorf; Ayten Shah; Allison Jhin; Janelle Noel-MacDonnell; Patrick Hecht; Bradley J Ferguson; Danielle Bruce; Michael Tilley; Zohreh Talebizadeh
Journal:  Front Psychiatry       Date:  2021-07-05       Impact factor: 4.157

Review 8.  Signalling Pathways Implicated in Alzheimer's Disease Neurodegeneration in Individuals with and without Down Syndrome.

Authors:  Carmen Martínez-Cué; Noemí Rueda
Journal:  Int J Mol Sci       Date:  2020-09-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.